| ||||||||
|
Equine
Monoclonal antibodies developed by US-VIRN: Monoclonal antibody development for the horse is based on a priority list for equine reagents that was initially developed during a Havemeyer workshop at Cornell University in 2003. Since then, this list was adjusted according to needs expressed by the equine research community. A need for equine reagents can still be expressed by contacting the species coordinator. Characterized monoclonal antibdies to equine cytokines and CD markers can be obtained from Cornell University. For these monoclonals, proof of specificity was obtained and is available in a published format. Click here for a list of the available monoclonal antibodies, confirmed applications, and links to the corresponding abstracts: http://courses2.cit.cornell.edu/eagnerlab/research/reagents/htm. Monoclonal antibodies will be made to: Cell Surface Molecules: CD14: Completed; 8 mAbs, detection of native protein confirmed (flow cytometry, cell sorting, Western blotting). CD23: Completed; 7 mAbs, detection of native protein confirmed (flow cytometry, Western blotting). CD25: Completed; 3 mAbs available (flow cytometry). CD28: Ongoing. CD40: Ongoing. FcεRIα: Characterization of mAbs ongoing. TCRα: Protein purified; fusion completed. TCRδ: Protein purification; fusion planned. CD19: Protein purified; fusion completed. NCR2: Protein purified; fusion completed. NCR3: Protein purified; fusion completed. IgD: In expression vector; protein expression planned. Cytokines and Chemokines: IL-4: Immunization with mammalian expressed protein completed; 1 mAb, detection of native protein confirmed (ELISA, flow cytometry, Western blotting, multiplex assay). IL-2: Immunization with yeast protein completed; 1 mAb; detection of native protein confirmed (ELISA, flow cytometry, multiplex assay). IL-10: Immunization with mammalian expressed protein completed; 3 mAbs; detection of native protein confirmed (ELISA, flow cytometry, multiplex assay). IL-6: Immunization with yeast protein; fusion completed; fusion has been repeated with protein expressed in mammalian cells. IL-1β: Immunization with yeast expressed protein; fusion completed; fusion has been completed with protein expressed in mammalian cells. IL-5: Immunization with yeast expressed protein; fusion completed, characterization of mAbs ongoing; detection of native IL-5 not yet confirmed. IL-13: Immunization with yeast expressed protein stopped; fusion has been repeated with protein expressed in mammalian cells. IL-17A: Immunization with yeast expressed protein; fusion completed, characterization of mAbs ongoing; ddetection of native IL-17A confirmed (flow cytometry, ELISA, multiplex assay). GM-CSF: Immunization with yeast expressed protein; fusion completed; needs repeat with protein expressed in mammalian cells. CCL2: Immunization with yeast expressed protein; fusion completed; several mAbs; characterization ongoing; detection of native CCL2 confirmed for 7 mAbs(ELISA, multiplex assay, flow cytometry). CCL3: Immunization with yeast expressed protein; fusion completed; 1 mAb; detection of native CCL3 confirmed (flow cytometry). CCL5: Immunization with yeast expressed protein; fusion completed; 1 mAb; characterization ongoing; weak detection of native CCL5(flow cytometry). CCL11: Immunization with yeast expressed protein; fusion completed; several mAbs; characterization ongoing; detection of native CCL11 confirmed (ELISA). CXCL9: Immunization with yeast expressed protein; fusion completed; needs repeat with protein expressed in mammalian cells. CXCL10: Immunization with yeast expressed protein; fusion completed; needs repeat with protein expressed in mammalian cells). Click here to download the survey form. Last updated: March 2013 |
 Dr. Bettina Wagner Species Coordinator, Equine Species Coordinator Bettina Wagner Species Collaborators Douglas Antczak
Samuel Black
Paul Lunn Robert Mealey James Moore Brett Sponseller |
|||||||
 | ||||||||
